$ABCL
AbCellera Biologics Inc. Stock $abcl

$abcl Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000170305723000040 Filed on November 02, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$9.179M	$6.599M
YoY Change	-57.4%	-93.49%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$19.07M	$17.84M
YoY Change	21.44%	5.66%
% of Gross Profit
Research & Development	$48.62M	$37.92M
YoY Change	72.14%	42.64%
% of Gross Profit
Depreciation & Amortization	$7.495M	$3.100M
YoY Change	-45.64%	24.0%
% of Gross Profit
Operating Expenses	$75.23M	$61.49M
YoY Change	26.82%	-3.39%
Operating Profit		-$54.89M
YoY Change		-245.46%
Interest Expense	$10.97M	$10.70M
YoY Change	-8.85%
% of Operating Profit
Other Income/Expense, Net	$6.482M	$15.61M
YoY Change	-214.36%	76.39%
Pretax Income	-$48.60M	-$39.28M
YoY Change	54.72%	-184.31%
Income Tax	-$1.452M	-$10.67M
% Of Pretax Income
Net Earnings	-$47.15M	-$28.61M
YoY Change	57.73%	-207.46%
Net Earnings / Revenue	-513.67%	-433.55%
Basic Earnings Per Share		-$0.10
Diluted Earnings Per Share	-$0.16	-$0.10
COMMON SHARES
Basic Shares Outstanding	290.2M shares	289.4M shares
Diluted Shares Outstanding		289.5M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$760.6M	$785.8M
YoY Change	39.58%	111.25%
Cash & Equivalents	52.20M cads	$172.4M
Short-Term Investments	$627.3M	$613.4M
Other Short-Term Assets	$55.81M	$71.23M
YoY Change	-25.99%	53.19%
Inventory	$1.107M	$1.200M
Prepaid Expenses
Receivables	$30.59M	$37.40M
Other Receivables	$33.79M	$38.10M
Total Short-Term Assets	$872.0M	$919.5M
YoY Change	-14.97%	-12.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$287.7M	$277.2M
YoY Change	32.42%	38.19%
Goodwill	$47.80M	$47.81M
YoY Change	-0.01%	0.0%
Intangibles	$120.4M	$124.1M
YoY Change	-8.42%	-12.96%
Long-Term Investments	$65.94M	$62.90M
YoY Change	-9.08%	-5.72%
Other Assets	$94.24M	$80.69M
YoY Change	103.41%	64.46%
Total Long-Term Assets	$616.1M	$592.7M
YoY Change	19.54%	16.96%
TOTAL ASSETS
Total Short-Term Assets	$872.0M	$919.5M
Total Long-Term Assets	$616.1M	$592.7M
Total Assets	$1.488B	$1.512B
YoY Change	-3.43%	-2.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$25.51M	$17.40M
YoY Change	72.03%	86.72%
Accrued Expenses	$13.87M	$11.90M
YoY Change
Deferred Revenue	$18.96M	$17.51M
YoY Change	-12.28%	156.9%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$119.0M	$110.2M
YoY Change	0.59%	3.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.906M	$5.051M
YoY Change	91.38%	76.79%
Total Long-Term Liabilities	$216.8M	$219.2M
YoY Change	14.5%	11.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$119.0M	$110.2M
Total Long-Term Liabilities	$216.8M	$219.2M
Total Liabilities	$335.8M	$329.4M
YoY Change	9.15%	8.99%
SHAREHOLDERS EQUITY
Retained Earnings	$279.8M	$326.9M
YoY Change	-34.35%	-28.32%
Common Stock	$874.3M	$857.3M
YoY Change	8.13%	7.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.152B	$1.183B
YoY Change
Total Liabilities & Shareholders Equity	$1.488B	$1.512B
YoY Change	-3.43%	-2.59%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$47.15M	-$28.61M
YoY Change	57.73%	-207.46%
Depreciation, Depletion And Amortization	$7.495M	$3.100M
YoY Change	-45.64%	24.0%
Cash From Operating Activities	-$19.58M	-$100.0K
YoY Change	-163.33%	-99.92%
INVESTING ACTIVITIES
Capital Expenditures	$14.41M	$20.90M
YoY Change	16.85%	-244.01%
Acquisitions
YoY Change
Other Investing Activities	-$9.901M	$8.100M
YoY Change	109.19%	-103.03%
Cash From Investing Activities	-$24.31M	-$12.80M
YoY Change	42.46%	-95.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.756M	6.600M
YoY Change	976.22%	-34836.84%
NET CHANGE
Cash From Operating Activities	-19.58M	-100.0K
Cash From Investing Activities	-24.31M	-12.80M
Cash From Financing Activities	3.756M	6.600M
Net Change In Cash	-40.13M	-6.300M
YoY Change	-382.64%	-98.46%
FREE CASH FLOW
Cash From Operating Activities	-$19.58M	-$100.0K
Capital Expenditures	$14.41M	$20.90M
Free Cash Flow	-$33.98M	-$21.00M
YoY Change	-282.89%	-81.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	abcl	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	886485000	usd
CY2023Q3	abcl	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	785840000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	25000000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	25000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	217255000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	277209000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	33150000	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	35708000	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3094000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	21612000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	17508000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	118320000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	110239000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76675000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	75185000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	19516000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16382000	usd
CY2022Q4	abcl	Deferred Government Contributions Noncurrent DeferredGovernmentContributionsNoncurrent	40801000	usd
CY2023Q3	abcl	Deferred Government Contributions Noncurrent DeferredGovernmentContributionsNoncurrent	84072000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	16054000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5308000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33178000	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33178000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3086000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5051000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	189310000	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	219176000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	329415000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	286851595	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	286851595	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	289777654	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	289777654	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	734365000	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	747914000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	74118000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	109384000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1391000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1460000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	426185000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	326937000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1233277000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1182775000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1540907000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1512190000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	101383000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6599000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	463879000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28846000	usd
CY2022Q3	us-gaap	Royalty Expense RoyaltyExpense	15035000	usd
CY2023Q3	us-gaap	Royalty Expense RoyaltyExpense	0	usd
	us-gaap	Royalty Expense RoyaltyExpense	64882000	usd
	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26582000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37917000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79634000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3468000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8579000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11080000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13792000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14369000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42470000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5150000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5735000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	63648000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-171154000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7609000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	31278000	usd
CY2023Q3	abcl	Grants And Incentives GrantsAndIncentives	2828000	usd
	abcl	Grants And Incentives GrantsAndIncentives	8879000	usd
	us-gaap	Net Income Loss NetIncomeLoss	188412000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-99248000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1293000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	439000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-997000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25331000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28171000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-99317000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.60
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	285322719	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	289496841	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	284639599	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	288750387	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	315818163	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	289496841	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	314183994	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	288750387	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1233277000	usd
CY2023Q1	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	489000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-630000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40110000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1208500000	usd
CY2023Q2	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	334000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16399000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	122000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-30528000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1025733000	usd
CY2022Q1	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	403000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	19347000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	307630000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	127036000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3089000	usd
	abcl	Grants And Incentives GrantsAndIncentives	10779000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1146000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2046000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-266000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3670000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8852000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15614000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16222000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45727000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	46587000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39276000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	270511000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-125427000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19963000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10666000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	82099000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-26179000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	26624000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-28610000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	187415000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15474000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1194827000	usd
CY2023Q3	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	257000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15862000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	439000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-28610000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1182775000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12291000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	507000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	168573000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1207507000	usd
CY2022Q2	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	232000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12113000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-211000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6785000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1212856000	usd
CY2022Q3	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	231000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11754000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1293000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	26624000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1250172000	usd
	us-gaap	Profit Loss ProfitLoss	188412000	usd
	us-gaap	Profit Loss ProfitLoss	-99248000	usd
	us-gaap	Depreciation Depreciation	6212000	usd
	us-gaap	Depreciation Depreciation	8874000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7844000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7985000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3686000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4926000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	36158000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	47735000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3304000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	6354000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	3675000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	35495000	usd
	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	-43966000	usd
	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	-9273000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-34934000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	28685000	usd
	abcl	Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable	-1151000	usd
	abcl	Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable	-1852000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4094000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-7238000	usd
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-4684000	usd
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-16253000	usd
	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-6630000	usd
	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-30377000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1226000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4319000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	246448000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24266000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58330000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	62516000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	560000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	670430000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	744674000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	418238000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	642913000	usd
	abcl	Proceeds From Receipt Of Grant Funding ProceedsFromReceiptOfGrantFunding	14100000	usd
	abcl	Proceeds From Receipt Of Grant Funding ProceedsFromReceiptOfGrantFunding	15023000	usd
	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	17370000	usd
	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	36757000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	19770000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	10214000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-335562000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-196785000	usd
	abcl	Repayment Of Liability For In Licensing Agreement And Contingent Consideration RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration	4383000	usd
	abcl	Repayment Of Liability For In Licensing Agreement And Contingent Consideration RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration	1049000	usd
	abcl	Proceeds From Debt And Exercise Of Stock Options ProceedsFromDebtAndExerciseOfStockOptions	2406000	usd
	abcl	Proceeds From Debt And Exercise Of Stock Options ProceedsFromDebtAndExerciseOfStockOptions	7640000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1977000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6591000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9963000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-479000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-101054000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-214939000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	501142000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	414651000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	400088000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	199712000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3115000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2290000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	396973000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197422000	usd
	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	2213000	usd
	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	12948000	usd
	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	46239000	usd
	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	3586000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of operationsAbCellera Biologics Inc.’s (the “Company”) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs and to develop its own pipeline of future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together.
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	29544395	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	315818163	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	289496841	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	314183994	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.</span></div>
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	26624000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28610000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	188412000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-99248000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	289496841	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	288750387	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.66
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	26624000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-28610000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	188412000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-99248000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	285322719	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	289496841	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	284639599	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	288750387	shares
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	30495444	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	288750387	shares
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.60
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11410471	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10913595	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50081069	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50544294	shares
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	235730000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	304239000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18475000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27030000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	217255000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	277209000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	25600000	usd
CY2023Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	72500000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0	usd
CY2023Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	13200000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	2500000	usd
	us-gaap	Depreciation Depreciation	6200000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	3100000	usd
	us-gaap	Depreciation Depreciation	8900000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	155143000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	31067000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	124076000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	7463000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4297000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4297000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4297000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4297000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	24651000	usd
	abcl	Number Of Joint Ventures NumberOfJointVentures	2	jointventure
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	64817000	usd
CY2023Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	38037000	usd
CY2022Q4	abcl	Prepaid Expense And Other Current PrepaidExpenseAndOtherCurrent	9064000	usd
CY2023Q3	abcl	Prepaid Expense And Other Current PrepaidExpenseAndOtherCurrent	32001000	usd
CY2022Q4	abcl	Materials And Supplies Current MaterialsAndSuppliesCurrent	1532000	usd
CY2023Q3	abcl	Materials And Supplies Current MaterialsAndSuppliesCurrent	1194000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5583000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5572000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6454000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6351000	usd
CY2022Q4	abcl	Deferred Grant Funding Current DeferredGrantFundingCurrent	6285000	usd
CY2023Q3	abcl	Deferred Grant Funding Current DeferredGrantFundingCurrent	6353000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	33150000	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	35708000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11754000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15862000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	34954000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	30924000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2000000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9100000	usd
CY2023Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	32300000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	18500000	usd
	abcl	Marketable Securities Weighted Average Life MarketableSecuritiesWeightedAverageLife	P0Y6M
CY2022Q3	us-gaap	Royalty Expense RoyaltyExpense	15000000	usd
	us-gaap	Royalty Expense RoyaltyExpense	64900000	usd
CY2023Q3	us-gaap	Royalty Expense RoyaltyExpense	0	usd
	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
abcl-20230930_cal.xml	Edgar Link	unprocessable
abcl-20230930_def.xml	Edgar Link	unprocessable
abcl-20230930_lab.xml	Edgar Link	unprocessable
0001703057-23-000040-index-headers.html	Edgar Link	pending
0001703057-23-000040-index.html	Edgar Link	pending
0001703057-23-000040.txt	Edgar Link	pending
0001703057-23-000040-xbrl.zip	Edgar Link	pending
abcelleradayhuleaseagree.htm	Edgar Link	pending
abcelleradayhuleaseagree001.jpg	Edgar Link	pending
abcelleradayhuleaseagree002.jpg	Edgar Link	pending
abcelleradayhuleaseagree003.jpg	Edgar Link	pending
abcelleradayhuleaseagree004.jpg	Edgar Link	pending
abcelleradayhuleaseagree005.jpg	Edgar Link	pending
abcelleradayhuleaseagree006.jpg	Edgar Link	pending
abcelleradayhuleaseagree007.jpg	Edgar Link	pending
abcelleradayhuleaseagree008.jpg	Edgar Link	pending
abcelleradayhuleaseagree009.jpg	Edgar Link	pending
abcelleradayhuleaseagree010.jpg	Edgar Link	pending
abcelleradayhuleaseagree011.jpg	Edgar Link	pending
abcelleradayhuleaseagree012.jpg	Edgar Link	pending
abcelleradayhuleaseagree013.jpg	Edgar Link	pending
abcelleradayhuleaseagree014.jpg	Edgar Link	pending
abcelleradayhuleaseagree015.jpg	Edgar Link	pending
abcelleradayhuleaseagree016.jpg	Edgar Link	pending
abcelleradayhuleaseagree017.jpg	Edgar Link	pending
abcelleradayhuleaseagree018.jpg	Edgar Link	pending
abcelleradayhuleaseagree019.jpg	Edgar Link	pending
abcelleradayhuleaseagree020.jpg	Edgar Link	pending
abcelleradayhuleaseagree021.jpg	Edgar Link	pending
abcelleradayhuleaseagree022.jpg	Edgar Link	pending
abcelleradayhuleaseagree023.jpg	Edgar Link	pending
abcelleradayhuleaseagree024.jpg	Edgar Link	pending
abcelleradayhuleaseagree025.jpg	Edgar Link	pending
abcelleradayhuleaseagree026.jpg	Edgar Link	pending
abcelleradayhuleaseagree027.jpg	Edgar Link	pending
abcelleradayhuleaseagree028.jpg	Edgar Link	pending
abcelleradayhuleaseagree029.jpg	Edgar Link	pending
abcelleradayhuleaseagree030.jpg	Edgar Link	pending
abcelleradayhuleaseagree031.jpg	Edgar Link	pending
abcelleradayhuleaseagree032.jpg	Edgar Link	pending
abcelleradayhuleaseagree033.jpg	Edgar Link	pending
abcelleradayhuleaseagree034.jpg	Edgar Link	pending
abcelleradayhuleaseagree035.jpg	Edgar Link	pending
abcelleradayhuleaseagree036.jpg	Edgar Link	pending
abcelleradayhuleaseagree037.jpg	Edgar Link	pending
abcelleradayhuleaseagree038.jpg	Edgar Link	pending
abcelleradayhuleaseagree039.jpg	Edgar Link	pending
abcelleradayhuleaseagree040.jpg	Edgar Link	pending
abcelleradayhuleaseagree041.jpg	Edgar Link	pending
abcelleradayhuleaseagree042.jpg	Edgar Link	pending
abcelleradayhuleaseagree043.jpg	Edgar Link	pending
abcelleradayhuleaseagree044.jpg	Edgar Link	pending
abcelleradayhuleaseagree045.jpg	Edgar Link	pending
abcelleradayhuleaseagree046.jpg	Edgar Link	pending
abcelleradayhuleaseagree047.jpg	Edgar Link	pending
abcelleradayhuleaseagree048.jpg	Edgar Link	pending
abcelleradayhuleaseagree049.jpg	Edgar Link	pending
abcelleradayhuleaseagree050.jpg	Edgar Link	pending
abcelleradayhuleaseagree051.jpg	Edgar Link	pending
abcelleradayhuleaseagree052.jpg	Edgar Link	pending
abcelleradayhuleaseagree053.jpg	Edgar Link	pending
abcelleradayhuleaseagree054.jpg	Edgar Link	pending
abcelleradayhuleaseagree055.jpg	Edgar Link	pending
abcelleradayhuleaseagree056.jpg	Edgar Link	pending
abcelleradayhuleaseagree057.jpg	Edgar Link	pending
abcelleradayhuleaseagree058.jpg	Edgar Link	pending
abcelleradayhuleaseagree059.jpg	Edgar Link	pending
abcelleradayhuleaseagree060.jpg	Edgar Link	pending
abcelleradayhuleaseagree061.jpg	Edgar Link	pending
abcelleradayhuleaseagree062.jpg	Edgar Link	pending
abcelleradayhuleaseagree063.jpg	Edgar Link	pending
abcelleradayhuleaseagree064.jpg	Edgar Link	pending
abcelleradayhuleaseagree065.jpg	Edgar Link	pending
abcelleradayhuleaseagree066.jpg	Edgar Link	pending
abcelleradayhuleaseagree067.jpg	Edgar Link	pending
abcelleradayhuleaseagree068.jpg	Edgar Link	pending
abcelleradayhuleaseagree069.jpg	Edgar Link	pending
abcelleradayhuleaseagree070.jpg	Edgar Link	pending
abcelleradayhuleaseagree071.jpg	Edgar Link	pending
abcelleradayhuleaseagree072.jpg	Edgar Link	pending
abcelleradayhuleaseagree073.jpg	Edgar Link	pending
abcelleradayhuleaseagree074.jpg	Edgar Link	pending
abcelleradayhuleaseagree075.jpg	Edgar Link	pending
abcelleradayhuleaseagree076.jpg	Edgar Link	pending
abcelleradayhuleaseagree077.jpg	Edgar Link	pending
abcelleradayhuleaseagree078.jpg	Edgar Link	pending
abcelleradayhuleaseagree079.jpg	Edgar Link	pending
abcelleradayhuleaseagree080.jpg	Edgar Link	pending
abcelleradayhuleaseagree081.jpg	Edgar Link	pending
abcelleradayhuleaseagree082.jpg	Edgar Link	pending
abcelleradayhuleaseagree083.jpg	Edgar Link	pending
abcelleradayhuleaseagree084.jpg	Edgar Link	pending
abcelleradayhuleaseagree085.jpg	Edgar Link	pending
abcelleradayhuleaseagree086.jpg	Edgar Link	pending
abcelleradayhuleaseagree087.jpg	Edgar Link	pending
abcelleradayhuleaseagree088.jpg	Edgar Link	pending
abcelleradayhuleaseagree089.jpg	Edgar Link	pending
abcelleradayhuleaseagree090.jpg	Edgar Link	pending
abcelleradayhuleaseagree091.jpg	Edgar Link	pending
abcelleradayhuleaseagree092.jpg	Edgar Link	pending
abcelleradayhuleaseagree093.jpg	Edgar Link	pending
abcelleradayhuleaseagree094.jpg	Edgar Link	pending
abcelleradayhuleaseagree095.jpg	Edgar Link	pending
abcelleradayhuleaseagree096.jpg	Edgar Link	pending
abcelleradayhuleaseagree097.jpg	Edgar Link	pending
abcelleradayhuleaseagree098.jpg	Edgar Link	pending
abcl-20230930.htm	Edgar Link	pending
abcl-20230930.xsd	Edgar Link	pending
abcl-20230930xexx311.htm	Edgar Link	pending
abcl-20230930xexx312.htm	Edgar Link	pending
abcl-20230930xexx321.htm	Edgar Link	pending
abcl-20230930xexx322.htm	Edgar Link	pending
abcl-20230930_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
abcl-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abcl-20230930_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABCL
AbCellera Biologics Inc. Stock $abcl

2023 Q4 Form 10-Q Financial Statement

#000170305723000040 Filed on November 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABCL AbCellera Biologics Inc. Stock $abcl

2023 Q4 Form 10-Q Financial Statement

#000170305723000040 Filed on November 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABCL
AbCellera Biologics Inc. Stock $abcl